MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model

References

• Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006; 93:1115-22; PMID:16804870; http://dx.doi.org/10.1002/bjs.5349
   PubMed Web of Science ®Google Scholar
• Thompson J, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5:344-66; PMID:1941355; http://dx.doi.org/10.1002/jcla.1860050510
   PubMed Web of Science ®Google Scholar
• Hara M, Sato M, Takahashi H, Takayama S, Takeyama H. Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year. Surg Today 2011; 41:1357-60; PMID:21922357; http://dx.doi.org/10.1007/s00595-010-4519-2
   PubMed Web of Science ®Google Scholar
• Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS, Chen PM. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol 2000; 30:12-6; PMID:10770562; http://dx.doi.org/10.1093/jjco/hyd003
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992; 84:1084-91; PMID:1619682; http://dx.doi.org/10.1093/jnci/84.14.1084
   PubMed Web of Science ®Google Scholar
• Hodge J. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996; 43:127-34; PMID:9001565; http://dx.doi.org/10.1007/s002620050313
   PubMed Web of Science ®Google Scholar
• Kim SG, Park MY, Kim CH, Sohn HJ, Kim HS, Park JS, Kim HJ, Oh ST, Kim TG. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Vaccine 2008; 26:6433-40; PMID:18812201; http://dx.doi.org/10.1016/j.vaccine.2008.08.072
   PubMed Web of Science ®Google Scholar
• Park JS, Kim HS, Park HM, Kim CH, Kim TG. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model. Vaccine 2011; 29:8642-8; PMID:21945963; http://dx.doi.org/10.1016/j.vaccine.2011.09.052
   PubMed Web of Science ®Google Scholar
• Ahn E, Kim H, Han KT, Sin JI. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model. Cancer Lett 2015; 356:676-85; PMID:25449428; http://dx.doi.org/10.1016/j.canlet.2014.10.019
   PubMed Web of Science ®Google Scholar
• Song K, Chang Y, Prud'homme GJ. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther 2000; 7:1527-35; PMID:11021590; http://dx.doi.org/10.1038/sj.gt.3301274
   PubMed Web of Science ®Google Scholar
• Song K, Chang Y, Prud'homme GJ. Regulation of T-helper-1 vs. T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther 2000; 7:481-92; PMID:10757021; http://dx.doi.org/10.1038/sj.gt.3301123
   PubMed Web of Science ®Google Scholar
• Conforti A, Peruzzi D, Giannetti P, Biondo A, Ciliberto G, La Monica N, Aurisicchio L. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. J Immunother 2009; 32:744-54; PMID:19561534; http://dx.doi.org/10.1097/CJI.0b013e3181aee1b6
   PubMed Web of Science ®Google Scholar
• Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G, La Monica N. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 2007; 26:47-58; PMID:18055074; http://dx.doi.org/10.1016/j.vaccine.2007.10.060
   PubMed Web of Science ®Google Scholar
• Mennuni C, Calvaruso F, Facciabene A, Aurisicchio L, Storto M, Scarselli E, Ciliberto G, La Monica N. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005; 117:444-55; PMID:15906358; http://dx.doi.org/10.1002/ijc.21188
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71:907-20; PMID:12050175
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-b signaling in T cells. Nat Med 2001; 7:1118-22; PMID:11590434; http://dx.doi.org/10.1038/nm1001-1118
   PubMed Web of Science ®Google Scholar
• Thomas DA, Massagué J. TGF-b directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer cell 2005; 8:369-80; PMID:16286245; http://dx.doi.org/10.1016/j.ccr.2005.10.012
   PubMed Web of Science ®Google Scholar
• Urban JL, Kripke ML, Schreiber HJ. Stepwise immunological selection of antigenic variants during tumor growth. J Immunol 1986; 137:3036-41; PMID:3489784
   PubMed Web of Science ®Google Scholar
• Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 2003; 111:1487-96; PMID:12750398; http://dx.doi.org/10.1172/JCI17656
   PubMed Web of Science ®Google Scholar
• Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999; 190:1033-8; PMID:10510093; http://dx.doi.org/10.1084/jem.190.7.1033
   PubMed Web of Science ®Google Scholar
• Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R. Blockade of the granzyme B/ perforin pathway through overexpression of the serine protease inhibitor PtdIns-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001; 98:11515-20; PMID:11562487; http://dx.doi.org/10.1073/pnas.201398198
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res 2011; 71:1406-17; PMID:21159666; http://dx.doi.org/10.1158/0008-5472.CAN-10-1296
   PubMed Web of Science ®Google Scholar
• Kim H, Kwon B, Sin JI. Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses. PLoS One 2013; 8:e83765; PMID:24391824; http://dx.doi.org/10.1371/journal.pone.0083765
   PubMed Web of Science ®Google Scholar
• Sin JI, Kim H, Ahn E, Jeon YH, Park WS, Lee SY, Kwon B. Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTLs and their infiltration into tumor sites. Cancer Lett 2013; 330:190-9; PMID:23219755; http://dx.doi.org/10.1016/j.canlet.2012.11.045
   PubMed Web of Science ®Google Scholar
• Noh KH, Lee YH, Jeon JH, Kang TH, Mao CP, Wu TC, Kim TW. Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res 2012; 72:1717-27; PMID:22337995; http://dx.doi.org/10.1158/0008-5472.CAN-11-3758
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Peruzzi D, Koo G, Wei WZ, La Monica N, Ciliberto G. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models. Hum Gene Ther 2014; 25:121-31; PMID:24195644; http://dx.doi.org/10.1089/hum.2013.103
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, La Monica N, Ciliberto G, Montero AJ. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med 2013; 11:62; PMID:23497415; http://dx.doi.org/10.1186/1479-5876-11-62
   PubMed Web of Science ®Google Scholar
• Sin JI, Sung JH, Suh YS, Lee AH, Chung JH, Sung YC. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of co-injection with a granulocyte,macrophage-colony stimulating factor gene. Vaccine 1997; 15:1827-33; PMID:9413089; http://dx.doi.org/10.1016/S0264-410X(97)88856-1
   PubMed Web of Science ®Google Scholar
• Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 2007; 13:341-9; PMID:17200373; http://dx.doi.org/10.1158/1078-0432.CCR-06-1838
   PubMed Web of Science ®Google Scholar
• Ye GW, Park JB, Park YJ, Choi YS, Sin JI. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic antitumor activity. Mol Ther 2007; 15:1564-70; PMID:17505485; http://dx.doi.org/10.1038/sj.mt.6300149
   PubMed Web of Science ®Google Scholar
• Sin JI, Park JB, Lee IH, Park D, Choi YS, Choe J, Celis E. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180-188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-g dependent manner: application of Trp2180-188 peptides. Cancer Immunol Immunother 2012; 61:1671-82; PMID:22382361; http://dx.doi.org/10.1007/s00262-012-1214-8
   PubMed Web of Science ®Google Scholar